Activity of imipenem/relebactam against Gram-negative bacilli from global ICU and non-ICU wards: SMART 2015–2016
Author:
Funder
Merck & Co., Inc.
Publisher
Elsevier BV
Subject
Microbiology (medical),Immunology,Immunology and Allergy,Microbiology
Reference29 articles.
1. The rising problem of antimicrobial resistance in the intensive care unit;Brusselaers;Ann Intensive Care,2011
2. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009–2011);Sader;Diagn Microbiol Infect Dis,2014
3. Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia;Sader;Int J Antimicrob Agents,2015
4. Antimicrobial resistance and resistance mechanisms of Enterobacteriaceae in ICU and non-ICU wards in Europe and North America: SMART 2011–2013;Lob;J Glob Antimicrob Resist,2015
5. Antimicrobial resistance in the intensive care unit: a focus on Gram-negative bacterial infections;MacVane;J Intensive Care Med,2017
Cited by 36 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Greece and Italy—SMART 2017–2021;European Journal of Clinical Microbiology & Infectious Diseases;2024-05-22
2. Global Resistance of Imipenem/Relebactam against Gram-Negative Bacilli: Systematic Review and Meta-Analysis;Current Therapeutic Research;2024
3. Activity of ceftolozane/tazobactam, imipenem/relebactam and ceftazidime/avibactam against clinical Gram-negative isolates—SMART United States 2019–21;JAC-Antimicrobial Resistance;2023-12-28
4. Susceptibility of Gram-negative isolates collected in South Korea to imipenem/relebactam and comparator agents—SMART 2018–21;JAC-Antimicrobial Resistance;2023-12-28
5. In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in the Asia-Pacific region: SMART 2017-2020;International Journal of Antimicrobial Agents;2023-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3